Literature DB >> 11994481

Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium.

Hélène D'Hauteville1, Shahid Khan, Duncan J Maskell, Anders Kussak, Andrej Weintraub, John Mathison, Richard J Ulevitch, Nicole Wuscher, Claude Parsot, Philippe J Sansonetti.   

Abstract

Shigella flexneri is a Gram-negative pathogen that invades and causes inflammatory destruction of the human colonic epithelium, thus leading to bloody diarrhea and dysentery. A type III secretion system that delivers effector proteins into target eukaryotic cells is largely responsible for cell and tissue invasion. However, the respective role of this invasive phenotype and of lipid A, the endotoxin of the Shigella LPS, in eliciting the inflammatory cascade that leads to rupture and destruction of the epithelial barrier, was unknown. We investigated whether genetic detoxification of lipid A would cause significant alteration in pathogenicity. We showed that S. flexneri has two functional msbB genes, one carried by the chromosome (msbB1) and the other by the virulence plasmid (msbB2), the products of which act in complement to produce full acyl-oxy-acylation of the myristate at the 3' position of the lipid A glucosamine disaccharide. A mutant in which both the msbB1 and msbB2 genes have been inactivated was impaired in its capacity to cause TNF-alpha production by human monocytes and to cause rupture and inflammatory destruction of the epithelial barrier in the rabbit ligated intestinal loop model of shigellosis, indicating that lipid A plays a significant role in aggravating inflammation that eventually destroys the intestinal barrier. In addition, neutralization of TNF-alpha during invasion by the wild-type strain strongly impaired its ability to cause rupture and inflammatory destruction of the epithelial lining, thus indicating that TNF-alpha is a major effector of epithelial destruction by Shigella.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994481     DOI: 10.4049/jimmunol.168.10.5240

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Shigella: a model of virulence regulation in vivo.

Authors:  Benoit Marteyn; Anastasia Gazi; Philippe Sansonetti
Journal:  Gut Microbes       Date:  2012-03-01

2.  Transcriptional adaptation of Shigella flexneri during infection of macrophages and epithelial cells: insights into the strategies of a cytosolic bacterial pathogen.

Authors:  Sacha Lucchini; Hong Liu; Qi Jin; Jay C D Hinton; Jun Yu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 3.  Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?

Authors:  Robert S Munford
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

Review 4.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

5.  Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens.

Authors:  V A Feodorova; L N Pan'kina; E P Savostina; O S Kuznetsov; N P Konnov; L V Sayapina; S V Dentovskaya; R Z Shaikhutdinova; S A Ageev; B Lindner; A N Kondakova; O V Bystrova; N A Kocharova; S N Senchenkova; O Holst; G B Pier; Y A Knirel; A P Anisimov; V L Motin
Journal:  Vaccine       Date:  2009-02-13       Impact factor: 3.641

6.  Discovery of new biosynthetic pathways: the lipid A story.

Authors:  Christian R H Raetz; Ziqiang Guan; Brian O Ingram; David A Six; Feng Song; Xiaoyuan Wang; Jinshi Zhao
Journal:  J Lipid Res       Date:  2008-10-29       Impact factor: 5.922

7.  Hexa-acylated lipid A is required for host inflammatory response to Neisseria gonorrhoeae in experimental gonorrhea.

Authors:  Xiyou Zhou; Xi Gao; Peter M Broglie; Chahnaz Kebaier; James E Anderson; Natalie Thom; Michael A Apicella; Gregory D Sempowski; Joseph A Duncan
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

Review 8.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Authors:  Ryan T Ranallo; Robert W Kaminski; Tonia George; Alexis A Kordis; Qing Chen; Kathleen Szabo; Malabi M Venkatesan
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

10.  Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Authors:  S Barnoy; K I Jeong; R F Helm; A E Suvarnapunya; R T Ranallo; S Tzipori; M M Venkatesan
Journal:  Vaccine       Date:  2009-11-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.